Open AccessRole of Src Tyrosine Kinases in Experimental Pulmonary Hypertension
Author(s) -
Soni Savai Pullamsetti,
Eva Berghausen,
Swati Dabral,
Aleksandra Tretyn,
Elsa Butrous,
Rajkumar Savai,
Ghazwan Butrous,
Bhola K. Dahal,
Ralf P. Brandes,
Hossein A. Ghofrani,
Norbert Weißmann,
Friedrich Grimminger,
Werner Seeger,
Stephan Rosenkranz,
Ralph T. Schermuly
Publication year - 2012
Publication title -
arteriosclerosis thrombosis and vascular biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.007
H-Index - 270
eISSN - 1524-4636
pISSN - 1079-5642
DOI - 10.1161/atvbaha.112.248500
Subject(s) - proto oncogene tyrosine protein kinase src , tyrosine kinase , kinase , sh3 domain , tyrosine protein kinase csk , receptor tyrosine kinase , pulmonary hypertension , chemistry , medicine , microbiology and biotechnology , biology , biochemistry , receptor
Pulmonary arterial hypertension is a progressive pulmonary vascular disorder with high morbidity and mortality. Compelling evidence suggests that receptor tyrosine kinases, such as platelet-derived growth factor (PDGF) are closely involved in the pathogenesis of pulmonary arterial hypertension. We investigated the effects of 2 novel PDGF inhibitors, nilotinib/AMN107 (Abl kinases/PDGF receptor inhibitor) and dasatinib/BMS-354825 (Abl kinases/PDGF receptor/Src inhibitor), on the proliferation and migration of pulmonary arterial smooth muscle cells (PASMCs) and on the hemodynamics and pulmonary vascular remodeling in experimental pulmonary hypertension, and determined the expression and regulation of Src family kinases.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom